Merck is injecting $1 billion into a new facility in Wilmington, Delaware to amp up U.S. drug production, especially for its ...

Immutep (ASX: IMM) has announced a solid median overall survival (OS) rate in Cohort B of its TACTI-003 (Keynote-C34) Phase ...

U.S. drug maker Merck is building a $1 billion facility in Wilmington, Delaware, aimed at increasing domestic production of ...

It's also a great place to start if you're looking for dividend stocks, as nearly every stock on the Dow Jones Industrial ...

Merck, the New Jersey-based drug giant, is spending $1 billion on a new Delaware factory to bring production of its best-selling cancer drug Keytruda to the U.S. and speed future medicines to market.

Summit, a specialist in oncology, has made excellent clinical progress with its leading candidate, ivonescimab. There's more where that came from, too; Ivonescimab just knocked it out of the park in ...

Arvinas is laying off about a third of its workforce, while Entrada is focusing more on Duchenne research. Elsewhere, Biogen talked down tariff impacts and Merck earmarked $1 billion for a biologics ...

Merck announced on Tuesday that it is investing $1 billion in a new Delaware plant to expand domestic production as it ...

In this week’s edition of InnovationRx, we look at a patent fight over the world’s top-selling drug, breakthroughs from the ...

Pembrolizumab combo before/after surgery and radiation significantly improved event-free survival in resectable advanced head ...

Exciting developments in cancer treatment were unveiled at the AACR meeting. Boehringer Ingelheim's zongertinib shows a 71% ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...